Jim Birchenough

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) climbed as much as 13.6 percent to $23.24 after Wells Fargo initiated the coverage of stock with an Outperform rating and a valuation range of $75-$81 on expected success for GBT440 in Sickle Cell Disease. "We view GBT440 a best-in-...

In a report published Monday, BMO Capital analyst Jim Birchenough downgraded the rating on ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) to Market Perform, while lowering the price target to $10, "following an updated review of recent progress and relative positioning of CAR-T and TCR-based therapies." The...

In a report published Thursday, BMO Capital analyst Jim Birchenough maintained his Outperform rating on Celgene Corporation (NASDAQ: CELG), with a price target of $163. "An early online publication by Celgene (CELG) for pleiotropic modulator CC- 122 in Blood suggests that while sharing a...

In a report published Thursday, BMO Capital analyst Jim Birchenough reiterated an Outperform rating on Five Prime Therapeutics Inc (NASDAQ: FPRX), with a $31 price target. The company, along with bluebird bio, Inc. (NASDAQ: BLUE), announced after market close on Wednesday that "the two companies...

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are down three percent following BMO analyst Jim Birchenough's note of customers cost preference of Roche's Avastin. Birchenough remarked that there has been “broad reconsideration” of use of “low-cost” Avastin over Regeneron's Eylea by patients....

Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) continue to surge following commercial availability of Iclusig and the UK Daily Mail's report on a potential buyout. On January 17, Ariad reported on the commercial availability of Iclusig^® (ponatinib) for adult patients with refractory chronic...

In a report published Tuesday, BMO Capital Markets analyst Jim Birchenough upgraded Tesaro (NASDAQ: TSRO) to Outperform from Market Perform, raising its price target to $46.00 from $36.00. According to the report, the upgrade follows the analyst's meeting with management. With an opportunity to...

Shares of Tesaro (NASDAQ: TSRO) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints. BMO Capital Markets analyst Jim Birchenough reported that investors had...

In a report published Thursday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Receptos (NASDAQ: RCPT), and raised the price target from $40.00 to $41.00. In the report, BMO Capital Markets noted, “Receptos reported 3Q13 operating results late yesterday and provided...

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Gilead Sciences (NASDAQ: GILD), and raised the price target from $85.00 to $90.00. In the report, BMO Capital Markets noted, “We are maintaining our Outperform rating on shares of GILD...

In a report published Monday, BMO Capital Markets analyst Jim Birchenough downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Outperform to Market Perform, and lowered the price target from $37.00 to $21.00. In the report, BMO Capital Markets noted, “We are downgrading our rating on...

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Regulus Therapeutics (NASDAQ: RGLS), and raised the price target from $10.00 to $15.00. In the report, BMO Capital Markets noted, “RGLS reported 2Q13 operating results late yesterday...